ECCB 14 -- Drug Development 2.0 -- Computational integrative biology methods for drug repurposing, target discovery and translational research.

The discovery of differentiated new medicines that provide clear benefits to patients remains challenging in spite of ever increasing investments. At the same time the quantity and diversity of patient related data continues to grow exponentially (pre-clinical data, clinical data, patient data, EHR, ‘OMICs data, and information associated with medicines in general). New business models are also emerging with stronger collaborations between the industry and the academia with large public private partnerships (PPPs such as IMI in the EU) or the use of crowd sourcing. The scientific community is starting to leverage this wealth of information in ways that have the potential to disrupt the traditional drug discovery and development process as we know it. This workshop also invites submissions that leverage and translate similar techniques and data sets to new application domains including Health Outcomes Research, Biotech and Agriculture.
This workshop intends to bring together leading members from academia, biotech and pharmaceutical companies to discuss how to maximize the use of this data deluge to accelerate the discovery of new medicines that will ultimately benefit patients.
Sun, 07/09/2014 (All day)
Palais de la Musique et des Congrès, Strasbourg, France